Why would procalcitonin perform better in patients with a SOFA-score less than 8?

van Oers, Jos A. H.; Nijsten, Maarten W.; de Jong, Evelien; Beishuizen, Albertus; de Lange, Dylan W.

Published in:
International Journal of Infectious Diseases

DOI:
10.1016/j.ijid.2019.09.027

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Letter to the Editor

Why would procalcitonin perform better in patients with a SOFA-score less than 8?

We read with great interest the meta-analysis by Peng and colleagues published in the International Journal of Infectious Diseases, in which they questioned the effectiveness of procalcitonin (PCT)-guided antibiotic therapy (Peng et al., 2019). They combined 16 randomized controlled trials (RCT), including 6452 critically ill patients with infections, and concluded that PCT-guided antibiotic therapy does not lead to a decreased short-term mortality. They also concluded that PCT-guided cessation of antibiotics only reduces short-term mortality in patients with a Sequential Organ Failure Assessment (SOFA) score of <8. It was, therefore, suggested that PCT-guided antibiotic therapy would be better suited to patients without multiple organ failure in the emergency department or general ward. Unfortunately, we think that this conclusion is neither correctly derived from the available data nor plausible!

The question regarding whether the severity of illness, as measured by the SOFA score, influences the effect of antibiotic treatment in all RCTs on PCT-guided therapy, is a valid research question. However, analyses should have been done at the individual patient level. Indeed, a recent patient-level meta-analysis on PCT-guided antibiotic therapy in 4482 septic patients in the intensive care unit (ICU), by Wirz and colleagues, showed that 30-day mortality was lower in the PCT-guided group (Wirz et al., 2018). Furthermore, when patients were divided into three subgroups by organ failure (SOFA 0 to 6, 7 to 10, and 10 to 24), the effects on mortality persisted. In our SAPS-trial on PCT guidance (De Jong et al., 2016), we included 1546 ICU patients and we demonstrated a significant reduction in 28-day mortality in the PCT group (p = 0.007). This effect on mortality persisted in the 587 patients with a SOFA score of ≥8 (p = 0.024).

Moreover, why should PCT-guided antibiotic therapy be better suited to patients in the emergency department and general ward or only patients with a SOFA score of <8? Obviously there are numerous non-infectious inflammatory processes, e.g. trauma or surgery, in which PCT can be elevated. Such conditions are frequently seen in emergency departments and general wards, but can also be encountered in the ICU. These conditions were well balanced between the two groups in previous meta-analyses. We therefore conclude that antibiotics should be started when an infection is suspected and that PCT is particularly suited for the cessation of antibiotic treatment, and we want to warn care-givers that the sensitivity and specificity of a single PCT measurement in the emergency department, general ward, or ICU are not high enough to start or withhold antibiotics based on PCT alone.

Author contributions

All authors (JvO, MN, EdJ, BB, and DL) made equal contributions.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Competing interests

No financial or non-financial competing interests.

Funding

No funding.

References


Jos A.H. van Oers*

Department of Intensive Care Medicine, Elisabeth Tweesteden Ziekenhuis, Tilburg, The Netherlands

Maarten W. Nijsten

Department of Critical Care, University Medical Center Groningen, University of Groningen, The Netherlands
Evelien de Jong
Department of Intensive Care Medicine, Rode Kruis Ziekenhuis,
Beverwijk, The Netherlands

Albertus Beishuizen
Department of Intensive Care Medicine, Medisch Spectrum Twente,
Enschede, The Netherlands

Dylan W. de Lange
Department of Intensive Care Medicine, University Medical Centre
Utrecht, Utrecht, The Netherlands

* Corresponding author at: Department of Intensive Care Medicine, Elisabeth Tweesteden Ziekenhuis, PO Box 90151, 5000 LC

E-mail addresses: jah.vanoers@etz.nl (J. van Oers),
m.w.n.nijsten@umcg.nl (M. Nijsten),
edejong@rkz.nl (E. de Jong),
B.Beishuizen@mst.nl (A. Beishuizen),
D.W.deLange@umcutrecht.nl (D. de Lange).

Corresponding Editor: Eskild Petersen, Aarhus, Denmark

Received 9 September 2019